Rigel Pharmaceuticals (RIGL) Tops Q3 Street Views

November 2, 2010 8:41 AM EDT
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) reports Q3 EPS of $0.96, versus the analyst estimate of $0.62. Revenue for the quarter was $72.3 million, which compares to the estimate of $55.78 million.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories


Add Your Comment